Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study
3d agoen
From the article
Conditions : Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; HER2-positive Gastric Cancer Interventions : Drug: Zanidatamab; Drug: Oxaliplatin; Drug: Capecitabine; Drug: S-1; Drug: Tislelizumab Sponsors : Zhifeng Zhao, PhD Not yet recruiting
Continue reading on clinicaltrials.govYou might also wanna read
Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial
doi.org·6d ago
Personalized Treatment Strategies for HER2-Positive Gastroesophageal Adenocarcinoma
This article discusses evolving strategies for personalized treatment of HER2-positive gastroesophageal adenocarcinoma (GEA). It features in
mdsc.pe·19d ago
ClinicalKey
clinicalkey.com·1mo ago
Nanoplatform co-delivering H2S and Ni2+ reverses chemoresistance and enhances immunotherapy in breast cancer
This research article presents a study on a novel nanoplatform (NiS@ALB) designed to combat chemoresistance in breast cancer. The authors de
cell.com·1d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.